Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yishen Tongluo Prescription is a Traditional Chinese Medicine (TCM) formulation developed by the Henan University of Chinese Medicine for the treatment of stage 3 diabetic kidney disease (DKD). Based on the TCM principles of tonifying the kidney ('Yishen') and dredging the collaterals ('Tongluo'), the prescription is intended to improve renal function and delay disease progression. It is currently being evaluated in randomized, placebo-controlled clinical trials to assess its clinical effectiveness, safety, pharmacokinetics, and underlying multi-omics mechanisms in patients with DKD.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on yishen tongluo prescription.